Browse by category

Publicly insured US individuals who are most likely to benefit from new drugs for diabetes and obesity are less likely to get them than...

Only about half of US employers (52%) say they effectively manage healthcare costs, according to Gallagher's 2024 US Physical & Emotional...

Roche has reported positive topline results from two arms of an ongoing multi-part Phase I clinical trial for CT-996, an investigational,...

Using a large language models (LLMs) to analyse over 391,000 unique discussions related to glucagon-like peptide-1 (GLP-1) receptor...

A network of proteins found in the central nervous system could be harnessed to increase the effectiveness and reduce the side effects of...

Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...

The largest study to date has reported that despite the explosion in demand for GLP-1s, 58% of patients discontinue use before reaching a...

A combination of GLP-1 agonists taken before metabolic and bariatric surgery may help patients with extreme obesity lower the risk of...

Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...

Although glucagon-like peptide-1 receptor agonists (GLP-1RAs) are highly effective for weight management and Type 2 diabetes treatment,...